BSE Prices delayed by 5 minutes... << Prices as on Sep 04, 2025 >>   ABB  5162.65 ATS - Market Arrow  [-0.49]  ACC  1839.75 ATS - Market Arrow  [-0.19]  AMBUJA CEM  567.55 ATS - Market Arrow  [-1.13]  ASIAN PAINTS  2568.85 ATS - Market Arrow  [0.57]  AXIS BANK  1050.2 ATS - Market Arrow  [-0.40]  BAJAJ AUTO  9067.4 ATS - Market Arrow  [-0.53]  BANKOFBARODA  233.95 ATS - Market Arrow  [-1.91]  BHARTI AIRTE  1880.3 ATS - Market Arrow  [-0.18]  BHEL  211.1 ATS - Market Arrow  [-2.67]  BPCL  312.85 ATS - Market Arrow  [-0.65]  BRITANIAINDS  6082.35 ATS - Market Arrow  [2.87]  CIPLA  1577.65 ATS - Market Arrow  [-0.09]  COAL INDIA  391.5 ATS - Market Arrow  [0.50]  COLGATEPALMO  2465.95 ATS - Market Arrow  [3.57]  DABUR INDIA  552.9 ATS - Market Arrow  [1.75]  DLF  758.2 ATS - Market Arrow  [-0.80]  DRREDDYSLAB  1253.4 ATS - Market Arrow  [-0.72]  GAIL  174.6 ATS - Market Arrow  [-1.91]  GRASIM INDS  2815.9 ATS - Market Arrow  [1.40]  HCLTECHNOLOG  1443.15 ATS - Market Arrow  [-1.57]  HDFC BANK  961.2 ATS - Market Arrow  [0.78]  HEROMOTOCORP  5351.05 ATS - Market Arrow  [0.04]  HIND.UNILEV  2667.25 ATS - Market Arrow  [0.13]  HINDALCO  738.75 ATS - Market Arrow  [-0.58]  ICICI BANK  1405.65 ATS - Market Arrow  [0.61]  INDIANHOTELS  774.5 ATS - Market Arrow  [0.10]  INDUSINDBANK  754.65 ATS - Market Arrow  [-1.78]  INFOSYS  1463.25 ATS - Market Arrow  [-1.08]  ITC LTD  415.85 ATS - Market Arrow  [1.06]  JINDALSTLPOW  1031.7 ATS - Market Arrow  [0.25]  KOTAK BANK  1949.9 ATS - Market Arrow  [-0.54]  L&T  3592.5 ATS - Market Arrow  [-0.22]  LUPIN  1939.4 ATS - Market Arrow  [-0.63]  MAH&MAH  3480.25 ATS - Market Arrow  [5.96]  MARUTI SUZUK  14655.65 ATS - Market Arrow  [-1.78]  MTNL  44.5 ATS - Market Arrow  [-1.00]  NESTLE  1212.55 ATS - Market Arrow  [1.50]  NIIT  113.7 ATS - Market Arrow  [-0.96]  NMDC  73.39 ATS - Market Arrow  [-1.20]  NTPC  330.2 ATS - Market Arrow  [-1.24]  ONGC  235.85 ATS - Market Arrow  [-1.38]  PNB  103.4 ATS - Market Arrow  [-0.86]  POWER GRID  282 ATS - Market Arrow  [-1.40]  RIL  1359.2 ATS - Market Arrow  [-0.90]  SBI  809.35 ATS - Market Arrow  [-0.34]  SESA GOA  435.65 ATS - Market Arrow  [-0.85]  SHIPPINGCORP  212.05 ATS - Market Arrow  [-4.46]  SUNPHRMINDS  1582.35 ATS - Market Arrow  [0.17]  TATA CHEM  938.6 ATS - Market Arrow  [-0.07]  TATA GLOBAL  1070.5 ATS - Market Arrow  [-3.08]  TATA MOTORS  687.55 ATS - Market Arrow  [-0.66]  TATA STEEL  166.75 ATS - Market Arrow  [-0.63]  TATAPOWERCOM  382.85 ATS - Market Arrow  [-1.59]  TCS  3095.75 ATS - Market Arrow  [-0.08]  TECH MAHINDR  1500.9 ATS - Market Arrow  [-0.53]  ULTRATECHCEM  12654.5 ATS - Market Arrow  [-0.59]  UNITED SPIRI  1321.7 ATS - Market Arrow  [-1.95]  WIPRO  244.95 ATS - Market Arrow  [-1.86]  ZEETELEFILMS  114.75 ATS - Market Arrow  [-1.25]  

Prevest Denpro Ltd.

Directors Report

BSE: 543363ISIN: INE0GAO01018INDUSTRY: Medical Equipment & Accessories

BSE   Rs 572.15   Open: 581.90   Today's Range 567.55
581.95
-9.80 ( -1.71 %) Prev Close: 581.95 52 Week Range 393.60
686.00
You can view full text of the latest Director's Report for the company.
Market Cap. (Rs.) 686.75 Cr. P/BV 7.16 Book Value (Rs.) 79.90
52 Week High/Low (Rs.) 686/394 FV/ML 10/200 P/E(X) 37.83
Bookclosure 03/09/2025 EPS (Rs.) 15.13 Div Yield (%) 0.00
Year End :2025-03 

Your Directors are pleased to present their 26th Annual Report on the business and operations
of the Company together with the Audited Financial Statements for the Financial Year ended
March R1 7D7R

FINANCIAL AND OPERATIONAL
PERFORMANCE

(Amount in Rs. Lakh)

Particulars

Standalone

Year ended
March 31, 2024

Year ended
March 31, 2024

Total Income (Revenue)

6717.76

5930.14

Less: Expenses

4290.49

3788.69

Profit/(Loss) before
taxation

2427.27

2141.46

Less: Tax Expense

607.14

529.09

Profit/(Loss)after tax

1820.13

1612.37

RESULTS OF OPERATIONS & STATE OF
COMPANY'S AFFAIRS

During FY 2024-25, the Company has earned a
profit before tax of Rs. 2427.27 Lakh and an after-tax
profit of Rs. 1820.13 Lakh, as against a profit before
tax of Rs. 2141.46 Lakh and an after-tax profit of
Rs.1612.37 Lakh during FY 2023-24. The Company
continues to focus on strengthening its operational
framework and establishing a solid foundation for
future growth. Your directors remain confident in the
Company's long-term prospects and are optimistic
about continued improvement in performance in the
years ahead

DIVIDEND

The Board of Directors, after reviewing the Company's
performance for the financial year 2024-25, has
recommended a dividend of Rs 1 (one) per equity
share. This reflects the Company's ongoing efforts to
enhance shareholder value and share the benefits of
its performance with all stakeholders. The proposed
dividend is subject to approval of the members at
the ensuing Annual General Meeting. In accordance
with applicable provisions of the Income-tax Act, 1961,
tax will be deducted at source from the dividend
amount payable to the Members

TRANSFER TO RESERVES

During the year under review, no amount is proposed
to be transferred to the General Reserve of the
Company.

SHARE CAPITAL

The paid-up share capital of the Company as on March
31, 2025, was Rs. 12,00,30,000, comprising 1,20,03,000
equity shares of Rs. 10 each, fully paid-up. During the
year under review, the Company has not issued any
additional shares. The Company has also not issued
any shares with differential voting rights or sweat
equity shares during the year, and accordingly, no
disclosures are required under Rule 8(13) of the
Companies (Share Capital and Debentures) Rules,

2014. Further, there are no shares held by trustees for
the benefit of employees; hence, the provisions of
Rule 16(4) of the said Rules are not applicable.

LISTING

The Company's equity shares continue to remain
listed on the SME Platform of BSE Limited under
Scrip Code 543363. The Company has duly paid the
annual listing feesfor the financial year 2024-25.

The Company has been listed on the SME Platform
for the requisite minimum period and has satisfied
the financial performance thresholds, compliance
requirements, and other eligibility norms stipulated
for migration to Main Board of BSE Limited.
Accordingly, a proposal has been placed in ensuing
Annual General Meeting for the approval of the
Members for migration of the Company from SME
Platform to Main Board of BSE Limited.

The Board is of the considered opinion that the
proposed migration will be a significant step forward
in the Company's growth journey as it is expected to
enhance the visibility and brand value of the Company
in the capital markets, provide access to a wider and
more diverse investor base including institutional
investors, improve liquidity in the Company's shares,
and strengthen its overall corporate image and
market credibility.

There are no instances of non-compliance with the
listing obligations, and the Company has complied
with all applicable rules, regulations, and guidelines
issued by BSE and SEBI during the year arrears.

PUBLIC DEPOSITS

The Company has not accepted any deposit falling
under Chapter V of the Companies Act, 2013 ("The
Act”) during the year under review. There were no
such deposits outstanding at the beginning and
end of the FY 2024-25.

SUBSIDAIRY AND ASSOCIATES COMPANIES

As on March 31, 2025, the Company has two wholly

owned subsidiaries viz

Denvisio Biomed Limited and Axiodent Inc.

During the year under review, the Company has made
an investment on February 01, 2025 in Axiodent Inc.,
a company incorporated under the laws of the State
of Delaware, USA by subscribing 4,000 shares, making
Axiodent Inc. a 100% subsidiary of Prevest Denpro
Limited.

CONSOLIDATED FINANCIAL STATEMENTS

In accordance with the provisions of the Companies
Act, 2013 ("the Act”) and the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, the
Audited Consolidated Financial Statements of the
Company form part of the Annual Report for the
financial year 2024-25.

Pursuant to Section 129(3) of the Act, a statement
containing the salient features of the financial
statements of the Company's subsidiaries, associates,
and joint ventures, in the prescribed format Form
AOC-1, is annexed to this Report as "Annexure A”.

In accordance with Section 136 of the Act, the
financial statements of the subsidiaries are also made

available on the Company's website at
www.prevestdenpro.com, under the Investors section.

AUDITORS & AUDITORS REPORT
STATUTORY AUDITORS AND STATUTORY AUDIT
REPORT

M/s. Mittal & Associates, Chartered Accountants (Firm
Registration No. 106456W), were appointed as the
Statutory Auditors of the Company at the 22nd Annual
General Meeting, to hold office for a term of five
consecutive years, until the conclusion of the 27th
Annual General Meeting, to be held for the financial
year ending March 31, 2026.

The Auditors' Report on the financial statements for
the financial year ended March 31, 2025, does not
contain any qualification, reservation, or adverse
remark. The Notes regarding the financial statements,
as referred to in the Auditors' Report, are self-explanatory
and do not require any further explanation from the
Board.

Further, pursuant to Section 143 of the Companies Act,
2013, read with the Companies (Audit and Auditors)

Rules, 2014, as amended, the Statutory Auditors have
not reported any instance of fraud committed by the
Company's officers or employees during the year
under review.

SECRETARIAL AUDITORS AND SECRETARIAL
AUDIT REPORT

Pursuant to the provisions of Section 204 of the Companies
Act, 2013, read with the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014,
the Company has appointed NKM & Associates, a
Company Secretary, to carry out the Secretarial Audit for
the financial year ended March 31, 2025. The Secretarial
Audit Report issued by the Secretarial Auditor is annexed
to the Report as "Annexure B”. The Report does not
contain any qualifications, reservations, or adverse
remarks.

Further, A certificate has been issued by M/s. NKM &
Associates., Company Secretaries in practice, confirming
that none of the Directors of the Company have been

debarred or disqualified from being appointed or
continuing as director by the Securities and
Exchange Board of India, Ministry of Corporate
Affairs or any such statutory authority. The certificate
is annexed as "Annexure C" to this Report.

INTERNAL AUDITORS

In accordance with the provisions of Section 138 of
the Companies Act, 2013, read with Rule 13 of the
Companies (Accounts) Rules, 2014, and other
applicable provisions, if any, the Company has
appointed M/s VNB and Company, Chartered
Accountants, as the Internal Auditors of the
Company for the financial year 2024-25.

The Internal Auditors periodically review the
adequacy of internal control systems and the
efficiency of business processes, and their findings
and recommendations are reviewed by the Audit
Committee from time to time for implementation
and continuous improvement.

COST AUDIT

Pursuant to the provisions of Section 148 of the
Companies Act, 2013, read with the Companies (Cost
Records and Audit) Rules, 2014, the Company has
appointed PAN & Associates, Cost Accountants, as
the Cost Auditors of the Company for the financial
year 2024-25 to carry out the audit of the cost
records maintained by the Company. The Company

PARTICULARS OF LOANS, GUARANTEES OR
INVESTMENTS

The particulars of loans, guarantees, and investments
made by the Company during the financial year, as
required under the provisions of Section 186 of the
Companies Act, 2013, are disclosed in the notes to the
financial statements, which form an integral part of
this Annual Report.

Further, pursuant to Paragraph A(2) of Schedule V of
the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, the details of loans
and advances given to subsidiaries have also been
provided in the notes to the financial statements
forming part of the Annual Report

PARTICULARS OF REMUNERATION OF
DIRECTORS AND CERTAIN SPECIFIED
EMPLOYEES:

Disclosures pertaining to remuneration and other
details as required under Section 197(12) of the
Companies Act, 2013, read with Rule 5(1) of the
Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014, and the Companies
(Particulars of Employees) Rules, 1975, are annexed to
this Report as
"Annexure D and Annexure E".

CONSERVATION OF ENERGY, TECHNOLOGY,
ABSORPTION AND FOREIGN EXCHANGE
EARNINGS AND OUTGO

Details required to be furnished pursuant to Section
134(3)(m) of the Companies Act, 2013 are as under:
Conservation of Energy: As a manufacturer of dental
materials and oral care products, our operations are
not energy-intensive by nature. However, the Company
continues to focus on responsible energy use. Efforts
are made to ensure electricity is used efficiently by
installing energy-saving devices and maintaining
equipment regularly to avoid unnecessary
consumption.

We have also adopted LED lighting, power-efficient
systems, and automated machinery that consume less
power while delivering consistent performance. While
these measures don't have a major financial impact
due to our industry profile, they reflect our ongoing
commitment to energy-conscious practice

Technology Absorption: We believe that technology
and quality go hand in hand, especially in the dental
care industry where precision and safety are paramount.
Over the past year, we have continued to invest in
improving our production capabilities by using modern
machinery and precision tools. Our production floors
are equipped with advanced quality control equipment,
and we have a dedicated team that oversees strict
compliance with manufacturing standards. The focus
remains on delivering products that meet both domestic
and international expectations. We also keep an eye on
global advancements and are prepared to upgrade
our infrastructure as and we continue offering reliable,

high-quality dental solutions to our customer

• Foreign Exchange Earned: Rs 35.87 Lakhs
(F.Y. 24-25)

• Foreign Exchange Used: Rs 130.23 Lakhs
(F.Y. 24-25)

RESEARCH AND DEVELOPMENT

The Company has a fully functional Research and
Development Centre at its manufacturing unit, which
continues to play an important role in supporting our
efforts to develop and improve dental materials and
oral care products.

During the year, the R&D team focused on
improving product stability, exploring new
formulations, and aligning our products with
changing industry requirements, especially
in terms of safety, performance, and regulatory
standards.

The Centre is equipped with the necessary tools and
facilities required for lab-scale development, testing,
and product evaluation.

CORPORATE GOVERNANCE:

As a Small and Medium-sized Enterprise (SME) listed
on the SME exchange of BSE Limited, the Company
is exempt from complying with certain corporate
governance provisions. Specifically, pursuant to
Regulation 15(2) of SEBI (Listing Obligations and
Disclosure Requirements) Regulation, 2015,
compliance with corporate governance requirements
specified in Regulations 17 to 27, clauses (b) to

(i) of sub-regulation 2 of Regulation 46, and Para C,

D, and E of Schedule V is not mandatory. Therefore,
corporate governance does not form part of this
Board's Report

However, Company is committed to adhering to
good corporate governance practices. We are
working diligently to ensure that our governance
practices align with the highest standards and
contribute to the overall integrity and
transparency of the organization.

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis Report for
the year under review, as required under Regulation
34(2)(e) of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, is provided in a
separate section and forms an integral part of the
Annual Report for the financial year ended March 31,
2025.

DIRECTORS AND KEY MANAGERIAL
PERSONNEL

Shri Sai Kalyan Surapaneni, DIN: 07330470, is liable
to retire by rotation at the ensuing 26 th Annual
General Meeting and, being eligible, offers himself for
re-appointment. Brief profile of the Director seeking
appointment/re-appointment have been provided in the
annexure to the Notice of the AGM.

The Company has also received Form DIR-8 from all
the Directors pursuant to Section 164(2) and Rule 14(1)
of the Companies (Appointment and Qualification of
Directors) Rules, 2014.

As on March 31, 2025, the Board of Directors of the
Company comprised of eight Directors, viz., four
Executive Directors, one Non-Executive Director and
three Independent Directors.

There was no change in Key Managerial Personnel
during the Financial Year ending March 31, 2025.

The composition of the Board and KMP along with the
number of other Directorships/Committee positions
held as on March 31, 2025, by the Directors is as
follows:

Sl.

No.

Name of the
Director

Category

Number of other
Directorships
held in other
public/Listed
companies

Number of Committee membership
held in other public companies
(limited to only Audit and
Stakeholders 'Relationship
Committees)

% of Equity
Shares held in
the

Company(%)

As Chairperson

As Member

1

Mr. Atul Modi

Chairman,

Managing

Director

1

Nil

Nil

37.52%

2

Mrs. Namrata Modi

Whole Time
Director, CFO

1

Nil

Nil

36.03%

3

Dr. Sai Kalyan
Surapaneni

Director

Research

1

Nil

Nil

0.00083%

4

Mr. Vaibhav Munjal

Director and CMO

1

Nil

Nil

Nil

5

Mrs. Niharika Modi

Non-Executive

Director

Nil

Nil

Nil

0.03%

6

CA Pardeep
Gandotra

Non-Executive

Independent

Director

Nil

Nil

Nil

Nil

7

Dr. Nikhil Shrikant

Non-Executive

Independent

Director

Nil

Nil

Nil

Nil

8

Dr. Sudeep
Haralakatte Murthy

Non-Executive

Independent

Director

Nil

Nil

Nil

Nil

9

Mr. Aman Sadhotra

Company
Secretary and
Compliance
Officer

Nil

Nil

Nil

Nil

NUMBER OF MEETINGS BOARD OF DIRECTORS

During the Financial Year 2024-25, four meetings of the Board were held on the following dates:

May 28, 2024; August 8, 2024; November 11, 2024; and February 1, 2025.

The gap between any two meetings did not exceed one hundred and twenty days. The necessary quorum was
present for all the meetings.

Attendance of Directors at the Board Meetings held during the financial year 2024-25:

Name of the Director

Board

Meetings entitled to attend

Board Meetings attended

Mr. Atul Modi

4

4

Mrs. Namrata Modi

4

4

Dr. Sai Kalyan Surapaneni

4

4

Mr. Vaibhav Munjal

4

4

Mrs. Niharika Modi

4

4

CA Pardeep Gandotra

4

4

Dr. Nikhil Shrikant Bobade

4

4

Dr. Sudeep Haralakatte Murthy

4

4

The Board Meetings are prescheduled, and adequate notice is given to the Board members. Board Meetings
are generally held at the registered office of the Company either through video conference or through physical
presence.

INDEPENDENT DIRECTORS

All Independent Directors have given declarations
that they meet the criteria of independence as laid
down under Section 149(6) of the Companies Act,
2013 and Regulation 16(1) (b) of the Listing
Regulations. In the opinion of the Board, the
Independent Directors, fulfil the conditions of
independence specified in Section 149(6) of the
Companies Act, 2013 and Regulation 16(1) (b) of the
Listing Regulations and are independent of
management.

During the financial year 2024-25, one (1) meeting of
the Independent Directors was held on February 06,
2025, inter-alia, to review the following:

(i) Review performance of non-independent directors
and the Board of Directors as a whole.

(ii) Review performance of the Chairperson of the
Company.

(iii) Assess the quality, quantity, and timeliness of the
flow of information between the management of the
Company and the Board of Directors that is necessary
for the Board to perform their duties effectively and
reasonably.

The meeting was attended by all the Independent
Directors. The familiarization program and other
disclosures as specified under Listing Regulations is
available on the Company's website
www.prevestdenpro.com

BOARD EVALUATION, INDUCTION AND
TRAINING OF BOARD MEMBERS

Pursuant to the provisions of the Companies Act, 2013
the Board has carried out an annual performance
evaluation of its own performance, the Independent
Directors individually as well as evaluation of the
working of the Board and its Committees, culture,

execution and performance of specific duties,
obligations, and governance.

The performance evaluation of the Independent
Directors has been completed. The Independent
Directors conducted the performance evaluation of
the Chairman and the Non-independent Directors.
The Board of Directors expressed their satisfaction
with the evaluation process.

PERFORMANCE EVALUATION CRITERIA FOR
THE INDEPENDENT DIRECTORS

The indicative criteria for valuation of performance
of the Independent Director that are provided in the
in terms of appointment are as under:

(i) Attendance and contribution at Board and
Committee meetings.

(ii) Appropriate mix of expertise, skills, behavior,
experience, leadership qualities, sense of sobriety
and understanding of business, strategic direction
to align company's value and standards.

(iii) Knowledge of finance, accounts, legal, investment,
marketing, foreign exchange/ hedging, internal
controls, risk

(iv) Management, assessment and mitigation,
business operations, processes and corporate
governance.

(v) Ability to create a performance culture that drives
value creation and a high quality of debate with
robust and probing discussions.

(vi) Effective decision-making ability.

(vii) Ability to open channels of communication with
executive management and other colleagues on
Board to maintain high standards of integrity and
probity.

(viii) His/her global presence, rational, physical, and
mental fitness, broader thinking, vision on
corporate social Responsibility etc.

(ix) His/her ability to monitor the performance of
management and satisfy himself/herself with
integrity of the financial

(x) Controls and systems in place by ensuring the
right level of contact with external stakeholders.

(xi) His/her contribution to enhance overall brand
image of the Company.

CRITERIA FOR SELECTION OF CANDIDATES FOR
APPOINTMENT AS DIRECTORS, KEY MANAGERIAL
PERSONNEL AND SENIOR MANAGEMENT
PERSONNEL

The Nomination and Remuneration Committee has laid
down well-defined criteria, in the Nomination and
Remuneration Policy, for selection of candidates for
appointment as Directors, Key Managerial Personnel and
Senior Management Personnel.

The said Policy is available on the Company's website
www.prevestdenpro.com

REMUNERATION POLICY FOR DIRECTORS, KEY
MANAGERIAL PERSONNEL AND SENIOR
MANAGEMENT PERSONNEL

The Nomination and Remuneration Committee has laid
down the framework for remuneration of Directors, Key
Managerial Personnel and Senior Management
Personnel in the Nomination and Remuneration Policy
recommended by it and approved by the Board. The
Policy, inter-alia, defines Key Managerial Personnel and
Senior Management Personnel of the Company and
prescribes the role of the Nomination and Remuneration
Committee. The Policy lays down the criteria for
identification, appointment and retirement of Directors
and Senior Management and lays down the framework
in relation to remuneration of Directors, Key Managerial
Personnel and Senior Management Personnel. The Policy
also provides for the criteria for determining qualifications,
positive attributes and independence of Director and
lays down the framework on Board diversity. The said
Policy is available on the Company's website
www.prevestdenpro.com

WHISTLE BLOWER POLICY/VIGIL MECHANISM

The Company has adopted a Whistle Blower Policy to
provide a formal mechanism to the Directors and
employees to report their concerns about unethical
behaviour, actual or suspected fraud or violation of the
Company's Code of Conduct or Ethics Policy. The Policy
provides for adequate safeguards against victimization
of employees who avail of the mechanism and provides
for direct access to the Chairman of the Audit Committee.
It is affirmed that no person has been denied access to
the Audit Committee. The said Policy is available on the
Company's website www.prevestdenpro.com

COMMITTEES OF THE BOARD
AUDIT COMMITTEE

Composition of the Committee and Meetings held and
attended by each member:

Name of the

Category

Meetings

Director

Held

Attended

Dr. Sudeep

Haralakatte

Murthy

Independent

Director

Chairperson

4

4

Dr. Nikhil

Shrikant

Bobade

Independent

Director

Member

4

3

Mrs. Namrata
Modi

Executive

Director

Member

4

4

Terms of Reference

The Audit Committee has interalia the following

mandate:

1. Oversight of the Company's financial reporting
process, examination of the financial statement and
the auditors' report thereon and the disclosure of its
financial information to ensure that the financial
statement is correct, sufficient, and credible.

2. Recommendation for appointments, re-appointment
and replacement, remuneration and terms of
appointment of auditors, including the internal
auditor, cost auditor and statutory auditor, of the
Company and the fixation of audit fee.

3. Approval of payments to statutory auditors for any
other services rendered by the Statutory Auditors of
the Company.

4. Reviewing, with the management, the Annual
Financial Statements and Auditor's Report the
resubmission to the Board for approval, with
reference to:

i. Matters required to be included in the Director's
Responsibility Statement to be included in the Board's
Report in terms of clause© of sub-section3 of section
134 of the Companies Act.

ii. Changes, if any, in accounting policies and practices
and reasons for the same.

iii. Major accounting entries involve estimates based
on the exercise of judgment by the management of
the Company.

iv. Significant adjustments made in the financial
statements arising out of audit findings.

v. Compliance with listing and other legal
requirements pertaining to financial statements

vi. Disclosure of any related-party transactions; and

vii. Qualifications/modified opinions in the draft audit
report.

5. Reviewing, with the management, the quarterly,
half-yearly and annual financial statements before
submission to the Board for approval.

6. Reviewing, with the management, the statement
of uses/application of funds raised through an
issue (public issue, rights issue, preferential issue,
etc.), the statement of funds utilized for purposes
other than those stated in the offer document/
prospectus/notice, and the report submitted by
the monitoring agency monitoring the utilization
of proceeds of a public or rights issue, and making
appropriate recommendations to the Board to take
up steps in this matter

7. Reviewing and monitoring the auditor's
independence and performance, as well as the
effectiveness of the audit process.

8. Formulating a policy on related-party transactions,
which shall include the materiality of related-party
transactions.

9. Approval or any subsequent modification of
transactions of the Company with related parties,
and omnibus approval for related-party
transactions proposed to be entered into by the
Company, subject to prescribed conditions.

10. Reviewing, at least on a quarterly basis, the details
of related-party transactions entered by the
Company pursuant to each of the omnibus
approvals given.

11. Scrutiny of inter-corporate loans and investments.

12. Valuation of the undertakings or assets of the
company, wherever necessary.

13. Evaluation of internal financial controls and risk
management systems.

14. Reviewing, with the management, the performance
of statutory and internal auditors, as well as the
adequacy of the internal control systems.

15. Reviewing the adequacy of the internal audit
function, if any, including the structure of the
internal audit department, staffing, and seniority
of the official heading the department, reporting

structure, coverage, and frequency of internal audit.

16. Discussion with internal auditors on any significant
findings and follow-up thereon.

17. Reviewing the findings of any internal investigations
by the internal auditors into matters where there is
suspected fraud or irregularity or a material failure
of internal control systems and reporting the matter
to the Board.

18. Discussion with statutory auditors before the audit
commences regarding the nature and scope of the
audit, as well as post-audit discussions to ascertain
any areas of concern.

19. Investigating the reasons for substantial defaults in
the payment to depositors, debenture holders,
shareholders (in case of non-payment of declared
dividends), and creditors.

20. Recommending to the Board of Directors the
appointment and removal of the external auditor,
fixation of audit fees, and approval for payment for
any other services.

21. Reviewing the functioning of the whistle blower
mechanism.

22. Approval of the appointment of the Chief Financial
Officer of the Company ("CFO") (i.e., the whole-time
finance director or any other person heading the
finance function or discharging that function), after
assessing the qualifications, experience, background,
etc., of the candidate.

23. Carrying out any other functions as provided under
the Companies Act, the SEBI Listing Regulations, and
other applicable laws.

24. Formulating, reviewing, and making recommendations
to the Board to amend the Audit Committee charter
from time to time.

25. Establishing a vigil mechanism for directors and
employees to report their genuine concerns or
grievances.

26. Carrying out any other function mentioned in the
terms of reference of the Audit Committee.

27. Performing any roles as prescribed under the
Companies Act and SEBI Listing Regulations.

NOMINATION AND REMUNERATION
COMMITTEE

Composition of the Committee and Meetings
attended by each member:

Name of the

Category

Meetings

Director

Held

Attended

Dr. Nikhil

Shrikant

Bobade

Independent

Director

Chairperson

1

1

Mrs. Niharika
Modi

Director

Member

1

1

Dr. Sudeep

Haralakatte

Murthy

Independent

Director

Member

1

1

Terms of Reference

The Nomination and Remuneration Committee has

the following mandate:

1. Formulating the criteria for determining
qualifications, positive attributes, and independence
of a director and recommending to the Board a
policy related to the remuneration of directors, key
managerial personnel, and other employees.

2. Formulating criteria for the evaluation of the
performance of Independent Directors and the
Board.

3. Devising a policy on Board diversity.

4. Identifying individuals qualified to become directors
of the Company and who may be appointed in
senior management positions in accordance with
the laid-down criteria and recommending their
appointment and removal to the Board. The
Company shall disclose the remuneration policy
and evaluation criteria in its annual report.

5. Analyzing, monitoring, and reviewing various
human resources and compensation matters.

6. Determining the Company's policy on specific
remuneration packages for executive directors,
including pension rights and any compensation
payment, and determining the remuneration
packages of such directors.

7. Recommending the remuneration, in any form,
payable to senior management personnel and
other staff (as deemed necessary).

8. Determining whether to extend or continue the
term of appointment of independent directors,

CORPORATE SOCIAL RESPONSIBILITY (CSR)
COMMITTEE

Your Company believes that Corporate Social
Responsibility (CSR) is an integral part of its business.
It seeks to operate its business in a sustainable
manner that benefits society at large and aligns with
the interests of its stakeholders. In accordance with
section 135 and Schedule VII of the Companies Act,
2013, the Board of Directors has constituted a CSR
Committee.

The CSR Committee has developed a CSR Policy,
which has been uploaded to the company's website
at www.prevestdenpro.com .

Name of the

Category

Meetings

Director

Held

Attended

Mr. Atul Modi

Managing

Director

Chairperson

1

1

Mrs. Niharika
Modi

Executive

Director

Member

1

1

Dr. Nikhil

Shrikant

Bobade

Independent

Director

Member

1

1

based on the performance evaluation of independent
directors.

9. Performing other activities delegated by the Board
and/or statutorily prescribed under any law to be
attended to by the Nomination and Remuneration
Committee.

10. Fulfilling such terms of reference as may be
prescribed under the Companies Act and SEBI Listing
Regulations.

^TAk’FHDI nFR RFI ATinM<;HIP mMMITTFF

Name of the

Category

Meetings

Director

Held

Attended

Mr. Atul Modi

Managing

Director

Chairperson

1

1

Mrs. Namrata
Modi

Executive

Director

Member

1

1

Dr. Nikhil

Shrikant

Bobade

Independent

Director

Member

1

1

Terms of Reference

The Stakeholders Relationship Committee is primarily
responsible for the following:

1. Considering and resolving the grievances of security
holders of the Company, including complaints related
to transfer/transmission of shares, non-receipt of
annual reports, dividend payments, and
dematerialization requests.

2. Reviewing measures taken for effective exercise of
voting rights by shareholders.

3. Monitoring the adequacy of services provided by the
Registrar & Share Transfer Agent.

4. Reviewing the status of complaints received from
shareholders and the redressal thereof.

5. Reviewing any investor correspondence or queries
received and ensuring timely responses and resolutions.

6. Carrying out any other function as prescribed under
the Companies Act, 2013, SEBI Listing Regulations,
or as may be delegated by the Board from time to
time.

During the financial year 2024-25, the Committee met
once to review and resolve shareholder grievances and
queries. All members of the Committee were present
during the meeting. Mr. Aman Sadhotra, Company
Secretary is the Compliance Officer of the Company

Terms of Reference

The Corporate Social Responsibility Committee has

the following mandate:

1. To formulate and recommend to the board a
corporate social responsibility policy that specifies
the activities to be undertaken by the company in
accordance with Schedule VII of the Companies Act
and the rules made there under. The committee
may also suggest revisions to the policy as decided
by the board.

2. To identify partners and programs for corporate
social responsibility initiatives.

3. To recommend the amount of expenditure to be
allocated for corporate social responsibility
activities and to distribute the funds among
various programs undertaken by the company.

4. To delegate responsibilities to the corporate social
responsibility team and oversee the proper
execution of all delegated tasks.

5. To review and monitor the implementation of
corporate social responsibility programs, providing

necessary directions for their proper execution and
timely completion.

6. To perform any other duties and functions as required
by the board to promote the company's corporate
social responsibility activities, and to exercise any
additional powers conferred upon the CSR Committee
under the provisions of Section 135 of the Companies
Act.

The annual report on CSR including a brief outline of
the CSR Policy and the activities undertaken during the
year under review is enclosed as "Annexure F" to this
Report.

GENERAL MEETINGS

The Annual General Meeting of the Company was held
at its registered office through VC for the Financial Year
2024-25.

Financial Year

Nature of
Meeting

Time (IST)

Date

2024-25

AGM

12.30 PM

06-09-2024

REGISTRAR AND SHARE TRANSFER AGENT
INFORMATION

The Company has appointed Bigshare Services Private
Limited as its Registrar and Share Transfer Agent (RTA)
to handle all investor-related services, including share
transfer, dematerialization, rematerialization, and other
related activities.

RTA Contact Details:

Bigshare Services Private Limited
Bharat Tin Works Building, 1st Floor,

Opp. Vasant Oasis, Makwana Road,

Marol, Andheri (East),

Mumbai - 400059, Maharashtra, India
Telephone: 91-22-62638200
Email ID:
jibu@bigshareonline.com

CODES AND POLICIES

All statutory codes and policies as required under the
Companies Act, 2013 and SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 have been

duly adopted by the Company.

These include, among others:

• Code of Conduct for Directors and Senior
Management

• Code of Fair Disclosure

• Insider Trading Policy

• Related Party Transaction Policy

• Nomination and Remuneration Policy

• Whistle-Blower Policy

• CSR Policy

• Risk Management Policy

• Archival and Document Preservation Policy

The above-mentioned policies are available on the
Company's website and can be
accessed at:
www.prevestdenpro.com

DISCLOSURE UNDER THE SEXUAL
HARASSMENT OF WOMEN AT WORKPLACE
ACT AND MATERNITY BENEFIT ACT

A. Sexual Harassment of Women at Workplace
In accordance with the provisions of the Sexual
Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013 and the
Companies (Accounts) Second Amendment Rules,
2025, the Company has implemented a
comprehensive Prevention of Sexual Harassment
(POSH) Policy.

An Internal Complaints Committee (ICC) is duly
constituted at the corporate level to deal with
complaints related to sexual harassment at the
workplace. The policy covers all categories of
employees, including permanent, temporary,
contractual, interns, and trainees.

During the financial year ended March 31, 2025, the
following is disclosed in accordance with the amended
rules:

Particulars

Number

Complaints received during the financial year

0

Complaints disposed of during the year

0

Complaints pending beyond 90 days

0

Total complaints pending as on March 31, 2025

0

The Company has also conducted awareness programs
and training for employees and ICC members during
the year. The ICC functions independently and ensures
a safe, respectful, and inclusive workplace environment.

B. Compliance with the Maternity Benefit Act,

1961

In accordance with Rule 8A of the Companies (Accounts)
Rules, 2014 (inserted via the Companies (Accounts)
Second Amendment Rules, 2025), the Company hereby
confirms that it has complied with the provisions of the
Maternity Benefit Act, 1961.

The Company remains committed to providing a safe,
equitable, and inclusive workplace for all its employees.

BOARD POLICIES:

In addition to above, the Board has also adopted below
mentioned policies:

(a) Policy for Determination of Materiality

(b) Policy on Materiality of Related Party Transactions
All above named policies and codes are available on
our website
www.prevestdenpro.com

INTERNAL FINANCIAL CONTROL AND THEIR
ADEQUACY

Your Company has an effective internal control and risk-
mitigation system that is continuously assessed and
strengthened through the implementation of new or
revised standard operating procedures. The internal
control system of the company is aligned with its size,
scale, and complexity of operations.

The primary focus of the internal audit is to test and
review controls, assess risks, evaluate business processes,
and compare controls with industry best practices. The
Audit Committee of the Board of Directors actively
reviews the adequacy and effectiveness of the internal
control systems and provides recommendations for
improvements. The company utilizes a robust
Management Information System, which is an integral
part of the control mechanism.

The Audit Committee, along with the Statutory
Auditors and Business Heads, is regularly briefed on
the findings of the internal audit and the corrective
actions taken. The audit function plays a vital role in
providing assurance to the Board of Directors.

Noteworthy audit observations and the corresponding
corrective actions implemented by the management
are presented to the Audit Committee.

To maintain objectivity and independence, the
Internal Audit function reports to the Chairman
of the Audit Committee.

RELATED PARTY TRANSACTIONS AND POLICY

All the transactions/contracts/arrangements of the
nature as specified in Section 188(1) of the Companies
Act, 2013 entered by the Company during the year
under review with related party(ies) are in the
ordinary course of business and on arms' length basis.
The particulars of related party transaction at arms'
length basis are disclosed in Board report and
marked as "Annexure G”.

TRANSFER OF UNCLAIMED DIVIDEND AND
EQUITY SHARES TO INVESTOR EDUCATION
AND PROTECTION FUND (IEPF)

Pursuant to Section 124 of the Act read with the
Investor Education and Protection Fund Authority
(Accounting, Audit, Transfer and Refund Rules), 2016
('the IEPF Rules'), during the year under review, no
amount of Unclaimed dividend and corresponding
equity shares were due to be transferred to IEPF
account.

RISK MANAGEMENT

During the financial year under review, the Company
has identified and evaluates elements of business risk.
Consequently, a Business Risk Management
framework is in place. The risk management
framework defines the risk management approach of
the Company and includes periodic review of such
risks and also documentation, mitigating controls and
reporting mechanism of such risks. The framework
has different risk models which help in identifying
risks trend, exposure and potential impact analysis
at a Company level as also separately for business.

ENVIRONMENT AND SAFETY

Your company is dedicated to ensuring a strong Safety,
Health, and Environmental (SHE) performance in
relation to its activities, products, and services. It takes
consistent measures to develop safer process
technologies and unit operations, investing significantly
in areas such as process automation to enhance safety
and reduce the potential for human error.

Additionally, the company emphasizes the importance
of training in process and behavior-based safety, as
well as adopting production processes that are both
safe and environmentally friendly. The company
maintains a continuous focus on improving its
management system to enhance safety and
environmental practices. Furthermore, your company
is committed to continuously taking further steps to
provide a safe and healthy environment. This
commitment reflects the ongoing dedication to
ensuring the well-being of employees, stakeholders,
and the community at large.

MATERIAL CHANGES AND COMMITMENTS, IF
ANY, AFFECTING FINANCIAL POSITION OF THE
COMPANY:

There were no significant changes or commitments
affecting the Company's financial position from the
end of the financial year to the date of this Report.

SIGNIFICANT AND MATERIAL ORDERS PASSED
BY THE REGULATORS OR COURTS

There are no significant and material orders passed by
the Regulators/Courts that would impact the going
concern status of the Company and its future operations.

NON-DISQUALIFICATION OF DIRECTORS

None of the Directors of the Company has been
debarred or disqualified from being appointed or
continuing as director of Companies.

SECRETARIAL STANDARDS

The Company has complied with the applicable SS-1
(Secretarial Standard on Meetings of the Board of
Directors) and SS-2 (Secretarial Standard on General
Meetings) issued by the Institute of Company
Secretaries of India.

ANNUAL RETURN

Pursuant to Section 92(3) of the Companies Act, 2013
read with Rule 12 of the Companies (Management
and Administration) Rules, 2014, a copy of the Annual
Return of the Company for Financial Year 2024-25
prepared in accordance with Section 92(1) of the Act
has been placed on the website and is available at
www.prevestdenpro.com .

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the provisions of section 134(5) of the
Companies Act, 2013, the Directors confirm that.

i. In the preparation of the Annual Accounts for the
year ended March 31, 2025, the applicable
accounting standards have been followed along with
proper explanation relating to departures, if any.

ii. Appropriate accounting policies have been selected
and applied consistently and such judgments and

iii. Estimates have been made that are reasonable
and prudent in order to provide a true and fair view
of the state of affairs of the Company as of March
31, 2025, and the profit of the Company for the
year ended on that date.

iv. Furthermore, proper and sufficient care has been
taken for the maintenance of adequate accounting
records in accordance with the provisions of the
Companies Act to safeguard the assets of the
Company and to prevent and detect fraud and
other irregularities the annual accounts have been
prepared on a “going concern" basis.

v. Proper internal financial controls are laid down
and such internal financial controls are adequate
and operating effectively.

vi. proper systems to ensure compliance with the
provisions of all applicable laws have been devised
and such systems were adequate and operating
effectively.

RESIDUAL DISCLOSURES

1. During the year under review no application was
made and no proceedings were pending against
the company under the Insolvency and Bankruptcy
Code, 2016 (31 of 2016) .

2. During the year under review there was no One
Time settlement with any bank or Financial
Institution.

ACKNOWLEDGEMENT AND APPRECIATION

Your Directors extend their heartfelt gratitude for the

support and cooperation received from Banks,
Government Authorities, Shareholders, Suppliers, and
Customers. They also acknowledge and express their
appreciation for the contributions made by the
employees at all levels, which have played a crucial
role in achieving the Company's goals.

Your Directors also highly value and appreciate the
dedication and commitment of every

Member of the Prevest family.

On behalf of the Board of Directors
For Prevest Denpro Limited

sd/- sd/-

Atul Modi Namrata Modi

Managing Director Whole-time Director

DIN: 00788272 DIN:00788266

Date: 13/08/2025
Place: Jammu

 
STOCKS A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z|Others

Mutual Fund A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others

Registered Office : 402, Nirmal Towers, Dwarakapuri Colony, Punjagutta, Hyderabad - 500082.
SEBI Registration No's: NSE / BSE / MCX : INZ000166638. Depository Participant: IN- DP-224-2016.
AMFI Registered Number - 29900 (ARN valid upto 24th July 2025) - AMFI-Registered Mutual Fund Distributor since June 2008.
Compliance Officer :- Name: Ch.V.A. Varaprasad, Mobile No.: 9393136201, E-mail: varaprasad.challa@rlpsec.com
Grievance Cell: rlpsec_grievancecell@yahoo.com , rlpdp_grievancecell@yahoo.com
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
Copyrights @ 2014 © RLP Securities. All Right Reserved Designed, developed and content provided by